Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The stock currently offers a 4% dividend yield ... We can see from my table above that Sanofi is undervalued by 55% to peers ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab ... 23 abstracts at the American Society of ...

Shares of NASDAQ SNY opened at $50.14 on Wednesday. The stock has a market cap of $127.25 billion, a PE ratio of 25.83, a ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after ... and trying to market this," CEO John Jacobs ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Shares of Sanofi (NASDAQ:SNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the four brokerages that are currently covering the stock, Marketbeat reports. Two analysts have ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

To decide if Sanofi SA (ADR) stock is a buy or sell, you’ll want to evaluate its fair market price or intrinsic value. Buying stocks that are going to go up typically means buying stocks that are ...